BCG immunotherapy optimization on an isoperimetric optimal control problem for the treatment of superficial bladder cancer

Pearl R (1929) Cancer and tuberculosis. Am J Hyg 9:97

Mathé G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, De Vassal F (1969) Active immunotherapy for acute lymphoblastic leukaemia. Lancet 293(7597):697–699

Zbar B, Rapp HJ (1974) Immunotherapy of guinea pig cancer with BCG. Cancer 34(8):1532–1540

Bloomberg SD, Brosmn SA, Hausman MS, Cohen A, Battenberg JD (1975) The effect of BCG on the dog bladder. Invest Urol 12:423–427

Dekernion JB, Golub SH, Gupta RK, Silverstein M, Morton DL (1975) Successful transurethral intralesional BCG therapy of a bladder melanoma. Cancer 36(5):1662–1667

Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180–183

Martinez-Pineiro JA, Muntanola P (1977) Nonspecific immunotherapy with BCG vaccine in bladder tumors: a preliminary report. Eur Urol 3:11–22

Chopin D, Saint F, Gattegno B (2001) Immunothérapie endovésicale: le bacille de Calmette-Guerin. Progrès en Urol 11(5):1065–1115

Neuzillet Y, Rouprêt M, Wallerand H, Pignot G, Larré S, Irani J, Pfister C (2012) Diagnostic et prise en charge des évènements indésirables survenant au décours des instillations endovésicales de BCG pour le traitement des tumeurs de vessie n’infiltrant pas le muscle (TVNIM): revue du comité de cancérologie de l’Association française d’urologie. Progrès en Urol 22(16):989–998

Wallerand H (2009) Instillations endovésicales et cancer de la vessie. Progrès en Urol 19(12):868–871

Saint F (2008) Immunothérapie par Bacille de Calmette-Guérin: quel protocole? Progrès en Urol 18:S99–S104

Cheng CW, Ng MT, Chan SY, Sun WH (2004) Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review. ANZ J Surg 74(7):569–572

Nanda S, Moore H, Lenhart S (2007) Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 210:143–156

De Pillis LG, Gu W, Fister KR, Head T, Maples K, Neal T, Murugan A, Yoshida K (2007) Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. Math Biosci 209:292–315

Bunimovich-Mendrazitsky S, Shochat E, Stone L (2007) Mathematical model of BCG immunotherapy in superficial bladder cancer. Bull Math Biol 69:1847–1870

Archuleta J, Mullens P, Primm TP (2002) The relationship of temperature to desiccation and starvation tolerance of the Mycobacterium avium complex. Arch Microbiol 178:311–314

Kuznetsov VA, Makalkin IA, Taylor MA, Perelson AS (1994) Nonlinear dynamics of immunogenic tumours: parameter estimation and global bifurcation analysis. Bull Math Biol 56:295– 321

Wigginton J, Kirschner D (2001) A model to predict cell-mediated immune regulatory mechanisms during human infection with mycobacterium tuberculosis. J Immunol 166:1951–1967

Lämmle M, Beer A, Settles M, Hanning C, Schwaibold H, Drews C (2002) Reliability of MR imaging-based virtual cystoscopy in the diagnosis of cancer of the urinary bladder. Am J Roentgenol 178:1483–1488

Spratt JA, Von Fournier D, Spratt JS, Weber EE (1993) Decelerating growth and human breast cancer. Cancer 71(6):2013–2019

Garira W, Musekwa SD, Shiri T (2005) Optimal control of combined therapy in a single strain HIV-1 Model. Electron J Differ Equ 52:1–22

Kamien MI, Schwartz NL (1991) Dynamic optimization: the calculus of variations and optimal control in economics and management, 2nd edn. Elsevier Science, New York

Pagano F, Bassi P, Piazza N, Abatangelo G, Drago Ferrante GL, Milani C (1991) Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 27:19–22

Takashi M, Wakai K, Ohno Y, Murase T, Miyake K (1995) Evaluation of a low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol 27:723–733

Mack D, Frick J (1995) Low-dose bacilli Calmette-Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada. Br J Urol 75: 1857

Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A (1996) Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, Grade 3 bladder cancer therapy. J Urol 156:1602–1605

Losa A, Hurle R, Lembo A (2000) Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 163:68–71

Boltyanskii VG, Gamkrelidze RV, Pontryagin LS (1956) Towards a theory of optimal processes, (Russian), Reports. Acad Sci USSR 110(1)

Fister KR, Panetta JC (2003) Optimal control applied to competing chemotherapeutic cell-kill strategies. SIAM J Appl Math 63:1954

Lenhart S, Workman J (2007) Optimal control applied to biological models. Chapman Hall/CRC, Boca Raton

Gumel AB, Lenhart S (2010) Modeling paradigms and analysis of disease transmission models, vol 75. American Mathematical Society, Providence